ABVX earnings: next report 2026-09-14, real EPS beat/miss history, analyst consensus Buy, P/E -23.48. Updated 2026-07-23.
Abivax (ABVX) Research Hub
Abivax (ABVX) trades on NASDAQ, FR in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 118.64 USD (-0.69%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -23.48, market cap 9.58B. This hub links to the full technical, earnings and options research available for ABVX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, FR |
| Last close | 118.64 USD (-0.69%) |
| 52-week range | 74.79 USD – 147.98 USD |
| Trend regime | Range |
| 14-day RSI | 29.8 (Oversold) |
| Trailing P/E | -23.48 |
| Market cap | 9.58B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-14 |
Available research for ABVX
Covered Call on ABVX: how it works, illustrative setup around the real 118.64 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ABVX: how it works, illustrative setup around the real 118.64 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ABVX: how it works, illustrative setup around the real 118.64 USD price, max profit/loss, breakeven and when to use it. Educational.
ABVX technical analysis: range, last 118.64 USD, RSI 29.8, 52w range 74.79 USD–147.98 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ABVX in?
Abivax (ABVX) is classified under Healthcare (Biotechnology), listed on NASDAQ, FR.
Is ABVX in an uptrend or downtrend?
As of 2026-09-11, ABVX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ABVX's trailing P/E ratio?
ABVX's trailing P/E is -23.48, with a market cap of 9.58B. See the earnings research page for full valuation detail.
When does ABVX next report earnings?
ABVX is next scheduled to report earnings on 2026-09-14, with a consensus EPS estimate of -0.95851 USD.